Review 4 important approvals passed by FDA in January 2020

Drug name: palforzia Pharmaceutical company: aimmune therapeutics Indications: it is suitable for children and adolescents aged 4 to 17 who are allergic to peanuts, and it is used to reduce the possible allergic reactions, including anaphylactic shock, which may occur when they are accidentally exposed to peanuts Drug Description: palforzia is a protein component extracted from peanut, which contains the main sensitizing protein, and the component is fixed Palforzia treatment consists of three stages, the initial dose stage can be given to patients aged 4-17, and the dose increasing stage and maintenance stage can be continued in patients aged 4 and above Approved on: January 31, 2020 Drug name: tazverik (tazemetostat) Pharmaceutical company: epizyme Indications: for the treatment of metastatic / locally advanced epithelioid sarcoma (ES) in adults and pediatric patients aged 16 and over who do not meet the requirements of complete resection Drug Description: tazverik is the only histone lysine methyltransferase approved so far N-methyltransferase) EZH2 inhibitor can inhibit the methylation of histone H3 lysine 27 (H3K27) and restore the expression of tumor suppressor gene Approved on: January 23, 2020 Drug name: tepezza (teprotumumab trbw) Pharmaceutical company: Horizon therapeutics Indications: for the treatment of thyroid associated ophthalmopathy (TED), also known as graves' ophthalmopathy (go), is a rare progressive autoimmune disease Drug Description: tepezza is an all human monoclonal antibody of IGF-1R, which can block IGF-1R and reduce the activity level of IGF-1 and TSH in eye cells of patients Approved on: January 21, 2020 Drug name: ayvakit (avapritinib) Pharmaceutical company: Blueprint medicines Indications: for the treatment of mutations (including PDGFRA) in exon 18 carrying PDGFRA gene D842v mutation) in adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST).